The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress

Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria ...
StockStory.org on MSN

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call

Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...

Vertex price target lowered to $24 from $34 at BofA

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.